High Barriers in Niche Areas: This Biotech Has No Competitors in the Short Term

In 2023, the U.S. cell therapy market reached $5.4 billion and is expected to grow 600% over the next decade to $37.85 billion. These cell therapies can be used to treat cancer, Parkinson's disease, and other neurological disorders, diabetes, provide skin cells for wound and burn repair, and help rebuild damaged cartilage and joints. Today, I'd like to share a biopharmaceutical company specializing in sports medicine and severe burn care — Vericel Corporation.

Founded in 1989 and headquartered in Cambridge, Massachusetts, Vericel Corporation was previously known as Aastrom Biosciences before officially changing its name in November 2014. In the same year, Vericel acquired Sanofi’s cell therapy and regenerative medicine business (which Sanofi had acquired when purchasing Genzyme in 2011), resulting in rapid expansion of the company’s business. As a regenerative medicine company, Vericel combines biological innovation with medical technology to create a highly differentiated portfolio of innovative cell therapies and specialty biologics for tissue repair and life restoration.

High Barrier Products with Strong Competitiveness

From a competitive standpoint, Vericel Corporation boasts a highly unique product portfolio due to significant barriers to entry for its existing products. Not only are there regulatory oversight and no biosimilar or 510(k) pathways to market, but the company’s newly approved products also benefit from patent protection and some degree of market exclusivity. Below are the details of the company's products.

Sports Medicine

Knee cartilage damage may be caused by acute or repetitive trauma from sports, exercise, or daily activities. When knee cartilage is damaged, it usually does not heal on its own. Without timely treatment, cartilage defects can progress to degenerative joint disease, osteoarthritis, and may require total knee replacement. Vericel Corporation’s Carticel (approved in 1997, acquired from Sanofi’s cell therapy and regenerative medicine business in 2014) was the first FDA-approved autologous cartilage repair product for repairing symptomatic cartilage defects in the femoral condyle caused by acute or repetitive trauma. It is suitable for patients who have not responded adequately to prior arthroscopic or other surgical repair procedures, such as debridement, microfracture, drilling, abrasion arthroplasty, or allogeneic/autologous bone grafts.

In 2016, Vericel Corporation launched a new product, MACI, the next generation of Carticel. MACI is autologous cartilage cells cultured on a porcine collagen membrane for treating adult knee cartilage defects. MACI is also the first FDA-approved tissue-engineered product that utilizes healthy knee cartilage from the patient to culture cells on a scaffold. Unlike Carticel, which is a cartilage cell suspension requiring suturing to the defect site, MACI consists of cells uniformly seeded on the collagen membrane, making the procedure simpler. MACI is implanted into focal defects through smaller incisions or mini-joint arthrotomy, with the surgeon only needing to trim it to fit the defect size for a precise match, using a ready-made fibrin sealant to secure it to the bone.

Currently, Vericel focuses on delivering MACI via arthroscopy for cartilage defects. Arthroscopic delivery of MACI enhances convenience for surgeons, reduces surgical time, and lessens post-operative trauma, ultimately alleviating patient pain and accelerating recovery. In August 2024, the FDA approved the sBLA for MACI, expanding the label. MACI Arthro combines the advantages of arthroscopic delivery with the long-term durability and mature clinical results of MACI. The custom-designed MACI Arthro instrument is intended to treat the most common defects in the market, supporting the company’s ongoing top-line revenue growth in the coming years.

Additionally, the company is assessing the feasibility and potential market opportunity for providing MACI treatment for ankle cartilage defects. This potential lifecycle extension and indication expansion require additional randomized clinical trials for ankle use. According to the current plan, MACIAnkle’s IND submission is expected in the first half of 2025, with clinical studies commencing in the second half of 2025. If approved, expanding MACI to the ankle will provide significant long-term growth potential for the product.

Burn Care

Epicel is a cultured autologous epidermal graft, the only FDA-approved cultured autologous epidermal graft product. Epicel is suitable for adult and pediatric patients with full-thickness or deep dermal burns covering ≥30% of the total body surface area (TBSA). This is an important treatment option for patients with severe burns who have limited skin available for autografts.

NexoBrid (anacaulase-bcdb) is a plant-based proteolytic enzyme product used for eschar removal in adult and pediatric patients with partial or full-thickness deep thermal burns. Approved at the end of 2022 for eschar removal in adults with partial deep or full-thickness thermal burns, it was launched in the U.S. in 2023. In mid-August 2024, Vericel announced that the FDA had approved NexoBrid for pediatric indications, to remove eschar from children with deep partial or full-thickness burns. For pediatric burn patients, NexoBrid is a minimally invasive alternative to traditional methods, ensuring children can use this innovative non-surgical treatment for rapid and effective healing of severe thermal burns.

Treatment of partial and full-thickness burns requires removal of damaged tissue or eschar, followed by grafting to close the wound. Early eschar removal and burn assessment are crucial first steps in treating burn patients, as early eschar removal helps reduce inflammation, slow or stop burn progression, and decrease the risk of infection and sepsis. Surgical eschar excision, which involves cutting away burned tissue until healthy tissue is reached, is the current standard of care. However, this surgical method has limitations, as it is non-selective, causing pain, bleeding, and loss of healthy tissue. Non-surgical eschar removal methods are also available, but their effectiveness is limited, and they have not proven to reduce the need for surgical eschar excision. NexoBrid, when applied topically, helps remove eschar while protecting viable tissue from damage. After four hours of treatment, the eschar is removed, and the wound bed is cleaned to assess burn depth, color changes, and bleeding patterns.

Revenue Growth Over the Past Decade

Over the past decade, Vericel Corporation’s total revenue has been on a steady upward trend, with a compound annual growth rate (CAGR) of over 20% since 2017. In 2021, the company’s total revenue was $156 million, increasing to $164 million in 2022, a modest growth. However, in 2023, the company’s total revenue increased to $198 million, reflecting a 20.17% increase compared to 2022.

In the past two years, the company’s net loss has gradually decreased, with the loss shrinking from $16.7 million in 2022 to $3.18 million in 2023, a reduction of 80.96%. This shows that the company’s core business has grown strongly in recent years, with improved operational efficiency and cost control yielding positive results.

For the first three quarters of 2024, the company’s total revenue reached $162 million, a 22.1% increase compared to the same period last year. MACI’s net revenue grew by 19.3%, reaching $129 million. Burn care products Epicel and NexoBrid generated total revenue of $32.87 million, a 35% increase from the previous year. The gross margin was 70%, up by 450 basis points from the previous year. Adjusted EBITDA grew by 103%, reaching $23.6 million, with an adjusted EBITDA margin of 15%, up by 580 basis points compared to the previous year.

As of September 30, 2024, the company had $151 million in cash and investments, with no other debt.

Future Growth Drivers

For the completed 2024 year, Vericel Corporation had initially expected total revenue to remain between $238 million and $242 million, reflecting a 20%-23% growth from the previous year. Gross margin was expected to rise to 72%, and adjusted EBITDA margin to 22%. Due to the significant underpenetration of the market for its core products, MACI and Epicel, as well as limited competition and high entry barriers, the company expects sustained growth in 2024 and beyond.

The newly approved NexoBrid and MACI Arthro are also expected to begin reporting full-year revenue in 2025, likely contributing at least a 20% increase in revenue, providing additional growth momentum for the company.

As of January 13, 2025, Vericel Corporation’s total market capitalization is $2.94 billion.